Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue rose 48% and royalty revenue 50%; HALO beat expectations and raised 2026 revenue and EBITDA guidance. Shares gained 27.2% through August 28 and remain above the 21-day average, supported by multiple product launches and licensing agreements.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Exceptional Profitability ⢠Elevated Leverage ⢠Liquidity Weakening HALO delivers exceptional profitability and cash flow, but high leverage, weakening liquidity, intangible-asset exposure, and premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Constructive monthly trend ⢠Short-term pullback ⢠Key support test Support Level: $106â107; stronger support at $103 Resistance Level: $110.76 HALO remains constructive over the last month but is pulling back below short-term averages; hold $106â107 for another $110.76 test, while a break below $103 would weaken the setup.
Sentiment & News
Key News Insights: ⢠Revenue acceleration ⢠Royalty expansion ⢠Institutional support Halozyme's accelerating revenue, royalty growth, raised guidance, and institutional buying reinforce a bullish growth outlook.
AI Summary
HALO is best viewed as a high-margin royalty platform benefiting from accelerating partner adoption of subcutaneous delivery, but after its sharp rally investors should demand sustained broad-based royalty growth and prioritize evidence of debt reduction over buybacks, given elevated leverage and a valuation with little room for partner-execution misses.
Description
Halozyme Therapeutics is a multinational biopharma technology company that develops and licenses a proprietary recombinant human hyaluronidase enzyme (rHuPH20) and the ENHANZE delivery technology to enable subcutaneous administration of biologics, small molecules and fluids. Its marketed offering includes Hylenex recombinant, and the company supplies or collaborates on subcutaneous formulations and pipeline programs across oncology and immunology with a range of large pharmaceutical partners. Halozyme was founded in 1998 and is headquartered in San Diego, with operations in multiple countries including Switzerland, Ireland, Belgium and Japan.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 28 | Sep 4 | HALO | Halozyme Therapeutics, Inc. | Q2 revenue rose 48% and royalty revenue 50%; HALO beat expectations and raised 2026 revenue and EBITDA guidance. Shares gained 27.2% through August 28 and remain above the 21-day average, supported by multiple product launches and licensing agreements. | Closed | +4.6% |
| Aug 11 | Aug 18 | HALO | Halozyme Therapeutics, Inc. | Strong biotech/pharma earnings catalyst: Q2 2026 revenue rose 48% YoY to $481M, royalty revenue rose 50%, management raised full-year revenue, adjusted EBITDA, and non-GAAP EPS guidance, added an Incyte ENHANZE collaboration, and stock broke out sharply on 2026-08-07. | Closed | +2.2% |